Types of Brain Stimulation Therapy

Electroconvulsive Therapy (ECT)

Electroconvulsive Therapy (ECT) is one of the oldest and most effective modern brain stimulation treatments. It involves the use of controlled electrical stimulation to induce a brief therapeutic seizure while the patient is under general anesthesia and muscle relaxation. Although ECT has been burdened by public stigma and outdated cultural portrayals, contemporary ECT is a medically supervised procedure with carefully controlled dosing, anesthesia, monitoring, and individualized electrode placement.

ECT is widely regarded as the “gold standard” somatic therapy for severe or treatment-resistant depression, particularly when symptoms are psychotic, life-threatening, or accompanied by catatonia (van Rooij et al., 2020). In the United States, ECT devices are FDA-regulated for specific severe indications, including catatonia and severe major depressive episodes associated with major depressive disorder or bipolar disorder in patients age 13 and older when treatment resistance or the need for rapid response is present.

ECT was pioneered by Italian neuropsychiatrists Ugo Cerletti and Lucio Bini in 1938 and introduced as a treatment for severe psychiatric illness, including schizophrenia and major depression (Paganin & Contini, 2025). Since then, the procedure has changed substantially. Modern ECT uses anesthesia, muscle relaxants, brief or ultrabrief pulse widths, and individualized stimulus dosing to reduce risks and improve tolerability.

Effectiveness

ECT has consistently demonstrated strong efficacy for severe depression, especially when rapid symptom relief is needed. It is particularly useful when depression is accompanied by suicidal risk, refusal to eat or drink, psychosis, or catatonia. The Prolonging Remission in Depressed Elderly (PRIDE) study found that 61.7% of 240 older adults with major depressive disorder achieved remission with ultrabrief right unilateral ECT, requiring an average of 7.3 sessions (van Rooij et al., 2020).

ECT may be especially valuable in older adults, partly because medications can be less tolerated and slower to work in this population. It also tends to act more rapidly than antidepressants, with some patients showing improvement within the first week of treatment. However, symptom relapse after ECT remains a significant clinical issue. Follow-up treatment, such as antidepressant medication, mood stabilizers, maintenance ECT, or psychotherapy, is often necessary to sustain remission (Nemeroff, et al., 2006).

Factors Influencing Clinical Effectiveness

The clinical effectiveness and cognitive side effects of ECT are influenced by several parameters:

Electrode Placement: Common placements include bitemporal, right unilateral, and bifrontal ECT. Bitemporal placement may produce robust effects but is also more associated with memory-related side effects. Right unilateral placement is often used to reduce cognitive burden, particularly when paired with ultrabrief pulse stimulation.

Stimulus Dose: The dose is calibrated relative to the individual’s seizure threshold. Higher doses may improve efficacy but can also increase cognitive side effects. Because seizure threshold varies across individuals and tends to increase with age, individualized dosing is essential.

Electrical Waveform: Brief-pulse and ultrabrief-pulse ECT differ in pulse width. Ultrabrief right unilateral ECT is often associated with fewer cognitive side effects, though it may require more sessions than brief-pulse treatment (van Rooij et al., 2020).

Side Effects

ECT is generally considered safe when properly administered, but it is not free of risk. Common short-term side effects include headache, nausea, muscle soreness, grogginess, and temporary confusion. Cognitive effects are the most discussed concern. Some patients experience anterograde amnesia, difficulty forming new memories during the treatment period, or retrograde amnesia, loss of memories from before treatment.

For many individuals, memory problems improve within days to weeks after treatment ends. However, some patients report more persistent autobiographical memory loss. Risk varies depending on electrode placement, pulse width, number of treatments, age, neurological vulnerability, and concurrent medications. Modern techniques seek to preserve ECT’s life-saving efficacy while reducing cognitive burden.

ECT’s ethical use requires informed consent, careful assessment, and ongoing monitoring. When used appropriately, it remains one of psychiatry’s most powerful interventions for severe mood disorders.

---

Transcranial Magnetic Stimulation (TMS)

Transcranial Magnetic Stimulation (TMS) is a noninvasive neuromodulation technique that uses magnetic fields to induce small electrical currents in targeted cortical regions. Unlike ECT, TMS does not require anesthesia, does not intentionally induce a seizure, and is not typically associated with significant cognitive side effects.

During TMS, a coil is placed against the scalp, often near the dorsolateral prefrontal cortex (DLPFC), a region involved in mood regulation and cognitive control. Magnetic pulses pass through the skull and influence neural excitability in targeted brain networks. The precise mechanisms remain under investigation, but TMS appears to influence membrane potentials, neurotransmitter systems, neurotrophic factors such as BDNF, and neuroplasticity (Akpinar et al., 2022).

Different stimulation frequencies can have different effects. Low-frequency TMS, often around 1 Hz, is generally associated with reduced cortical excitability, while high-frequency stimulation may increase excitability (Arubuolawe et al., 2024).

Uses and Efficacy

TMS is best established for treatment-resistant depression. The FDA first permitted marketing of a TMS device for major depression in 2008, initially for adults with major depressive disorder who had not achieved satisfactory improvement from one antidepressant medication in the current episode. Since then, FDA-cleared or FDA-permitted uses of TMS have expanded to include additional device- and protocol-specific indications, including obsessive-compulsive disorder and certain migraine-related applications. NIMH notes that rTMS has FDA-cleared uses for several conditions, including treatment-resistant depression, OCD, migraines, depression with anxiety symptoms, and smoking dependence. However, TMS is not generally considered as rapidly or broadly effective as ECT for the most severe depressive episodes.

Clinical outcomes vary widely depending on diagnosis, stimulation site, protocol, severity of illness, and prior treatment resistance. Some studies report response rates between 30% and 60%, while specific clinical samples may show higher or lower rates (Akpinar, et al., 2022). TMS is often attractive because it is outpatient-based, does not require anesthesia, and usually allows patients to resume normal activities immediately after treatment.

Types of TMS

Repetitive TMS (rTMS): Repetitive TMS delivers pulses in trains over repeated sessions. High-frequency stimulation is often applied to the left DLPFC in depression, while low-frequency stimulation may be applied to the right DLPFC.

Deep TMS (dTMS): Deep TMS uses specialized coils, such as H-coils, designed to stimulate broader and deeper brain regions than standard rTMS. It has been studied for depression, OCD, and smoking cessation (Paganin & Contini, 2025).

Theta Burst Stimulation (TBS): Theta burst stimulation uses patterned bursts of stimulation and can be delivered in shorter sessions. Intermittent theta burst stimulation (iTBS) has gained attention for depression because it may reduce treatment time while maintaining clinical benefit.

Accelerated TMS Protocols: Accelerated protocols compress treatment into a shorter time frame by delivering multiple sessions per day. The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol is one well-known example. These protocols are promising, but they should be described carefully. Early studies show rapid antidepressant effects in selected samples, but broader real-world effectiveness, durability, accessibility, and standardized implementation remain active areas of research. NIMH notes that accelerated rTMS protocols may work more quickly and deliver multiple sessions in one day, but ongoing research continues to refine optimal use.

Side Effects

TMS is generally well tolerated. Common side effects include scalp discomfort, mild headache, facial muscle twitching, dizziness, and brief lightheadedness. Seizures are possible but rare when expert safety guidelines are followed. Because TMS does not require anesthesia and does not typically impair memory, it is often considered a lower-burden option than ECT for appropriate patients. However, long-term outcomes and optimal maintenance strategies remain important areas of ongoing study.

---

Combination Transcranial Magnetic Stimulation with Ketamine (CTK)

Combination Transcranial Magnetic Stimulation with Ketamine (CTK) refers to the clinical or investigational pairing of TMS with ketamine-based treatment for treatment-resistant depression. Ketamine is a dissociative anesthetic and noncompetitive NMDA receptor antagonist that can produce rapid antidepressant effects in some individuals.

Efficacy

Early research suggests that combining TMS and ketamine may benefit some patients with treatment-resistant depression, particularly those who have not responded to either intervention alone. Some studies report substantial and sustained improvement in depressive symptoms, but the evidence base remains limited by small samples, heterogeneous protocols, and a lack of large randomized controlled trials (Arubuolawe et al., 2024).

For this reason, CTK should be presented as promising but not yet standardized. It may represent a future direction in precision psychiatry, but clinicians and patients must be cautious about overinterpreting preliminary findings.

Mechanisms

TMS and ketamine appear to influence depression through partly overlapping and partly distinct pathways. Both may enhance neuroplasticity, alter glutamatergic signaling, and influence brain-derived neurotrophic factor (BDNF). Their combination may theoretically create a window in which disrupted neural circuits become more responsive to adaptive change (Arubuolawe et al., 2024).

However, mechanism-based explanations remain provisional. Depression is not a single-circuit disorder, and response likely depends on patient characteristics, illness subtype, treatment history, and comorbid conditions.

Side Effects and Limitations

Reported side effects of CTK are often mild and transient, including nausea, vertigo, dissociation, perceptual changes, and local discomfort. Ketamine also carries clinical concerns related to blood pressure changes, dissociation, misuse potential, and the need for careful medical monitoring.

At present, CTK should be discussed as an emerging treatment strategy rather than an established standard of care. Larger randomized trials are needed to clarify efficacy, safety, dosing, sequencing, and long-term outcomes.

---

Deep Brain Stimulation (DBS)

Deep Brain Stimulation (DBS) is an invasive neurosurgical technique involving implanted electrodes that deliver electrical stimulation to specific brain regions. DBS is well established for several movement disorders, including Parkinson’s disease, dystonia, and essential tremor. Its psychiatric applications are more limited and remain an area of active investigation.

DBS is sometimes better understood as “deep brain neuromodulation” because its effects are not simply excitatory. It can disrupt pathological synchronization, alter network dynamics, influence neurotransmitter release, and reshape communication between brain regions (Ashkan et al., 2017; Chiken & Nambu, 2015).

Mechanisms

DBS likely works through multiple mechanisms:

Network Modulation: DBS may interrupt maladaptive firing patterns within dysfunctional circuits.

Axonal Activation: Some effects may occur through stimulation of white matter pathways rather than only gray matter targets.

Neurotransmitter Effects: DBS can influence downstream neurotransmitter systems, including dopamine, serotonin, and glutamate.

Neuroplasticity: Long-term stimulation may promote gradual reorganization of neural networks, which may explain why mood and compulsive symptoms can take weeks or months to change.

Uses and Efficacy

Movement Disorders: DBS is well established for Parkinson’s disease, tremor, and dystonia (Hariz et al., 2013).

Obsessive-Compulsive Disorder: DBS has shown promise for severe, treatment-resistant OCD. In the United States, DBS for OCD is FDA-authorized under a Humanitarian Device Exemption, meaning it is available for a narrowly defined population while further evidence continues to develop.

Depression: DBS for depression remains investigational. Early open-label studies generated enthusiasm, but larger controlled trials have produced mixed results. Research continues to explore improved targets, patient selection, biomarkers, and closed-loop systems (van Rooij et al., 2020).

Chronic Pain, Epilepsy, Addiction, and Eating Disorders: DBS has been explored for several additional conditions, though evidence varies by diagnosis and target (Hariz et al., 2013).

Side Effects and Limitations

DBS carries risks associated with brain surgery, including bleeding, infection, device complications, headache, confusion, mood changes, and cognitive effects. It also requires long-term device management, programming, battery replacement, and specialized follow-up care.

The ethical issues are significant. DBS can influence mood, motivation, impulse control, and subjective experience. In psychiatric use, clinicians must consider decisional capacity, informed consent, identity concerns, and the vulnerability of severely ill patients.

---

Vagus Nerve Stimulation (VNS)

Vagus Nerve Stimulation (VNS) involves electrical stimulation of the vagus nerve, traditionally through an implanted pulse generator placed in the chest and connected to the left cervical vagus nerve. Originally developed for epilepsy, VNS later received FDA approval through the Premarket Approval pathway as an adjunctive long-term treatment for chronic or recurrent depression. The FDA approval order specifies use in adults age 18 and older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments.

Mechanisms

Approximately 80% of vagus nerve fibers are afferent, carrying sensory information from the body to the brain. These fibers project to the nucleus tractus solitarius, which connects with brainstem, limbic, and cortical regions involved in mood regulation, arousal, and stress response. VNS may influence serotonergic and noradrenergic systems, both of which are implicated in depression and antidepressant response (Nemeroff et al., 2006).

VNS reminds us that the nervous system is not confined to the head. Mood regulation emerges through communication between brain and body, including autonomic pathways that influence arousal, inflammation, heart rate, and emotional regulation.

Uses and Efficacy

Epilepsy: VNS is approved for pharmacoresistant focal-onset seizures and has demonstrated long-term seizure-reduction benefits in some patients (Middlebrooks et al., 2024).

Treatment-Resistant Depression: VNS was approved for treatment-resistant depression in 2005. Clinical studies suggest that improvement may unfold gradually over months rather than days or weeks. Response and remission rates may increase over time, but findings have been mixed, and VNS remains infrequently used for depression (Nemeroff, et al., 2006).

Transcutaneous VNS: Noninvasive or transcutaneous VNS is being studied as a potentially more accessible alternative to implanted VNS. However, tVNS is still investigational for depression and should not be presented as equivalent to implanted VNS.

Side Effects

Common side effects of implanted VNS include voice changes, hoarseness, cough, throat discomfort, dyspnea, paresthesias, and pain or infection at the implantation site. Because the device is implanted, surgical risks and device complications must also be considered. Noninvasive VNS may reduce some surgical risks, but optimal protocols and long-term effects remain under study.

---

Transcranial Direct Current Stimulation (tDCS)

Transcranial Direct Current Stimulation (tDCS) is a noninvasive technique that applies a weak electrical current to the scalp through electrodes, often at intensities of 1–2 mA for 10–30 minutes per session. Unlike TMS, tDCS does not directly trigger neuronal firing. Instead, it subtly shifts neuronal excitability, making targeted regions more or less likely to activate.

Mechanisms

Anodal stimulation is generally thought to increase cortical excitability by depolarizing neuronal membranes, while cathodal stimulation may reduce excitability through hyperpolarization. These effects are not absolute, and outcomes depend on electrode placement, current intensity, duration, baseline brain state, and individual neurobiology (Gwon et al., 2023).

Uses and Efficacy

Depression: tDCS has shown small to moderate benefit for depression, particularly when targeting the left DLPFC. However, it is generally less established than ECT or TMS and does not appear to be as effective for severe treatment-resistant depression (van Rooij et al., 2020).

Nicotine Addiction: tDCS may reduce craving and smoking behavior in some individuals, possibly through modulation of executive control networks involved in craving regulation (Gwon et al., 2023).

Cognitive and Home-Based Applications: Because tDCS devices are relatively inexpensive and portable, researchers are exploring home-based and remotely supervised use. However, accessibility can be a double-edged sword. Self-administration without clinical guidance may produce inconsistent dosing, improper electrode placement, unrealistic expectations, or unmonitored side effects.

Side Effects and Advantages

Common side effects include tingling, itching, scalp discomfort, fatigue, mild burning sensations, and headache. Serious adverse effects are uncommon in supervised research and clinical settings. Still, tDCS remains a developing intervention with variable evidence across conditions.